4/23
08:00 am
dare
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
High
Report
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
4/11
08:00 am
dare
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
Medium
Report
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
4/1
08:09 am
dare
Daré Bioscience, Inc. (NASDAQ: DARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Daré Bioscience, Inc. (NASDAQ: DARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
3/28
08:09 am
dare
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update [Yahoo! Finance]
High
Report
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update [Yahoo! Finance]
3/28
08:00 am
dare
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
High
Report
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
3/21
08:00 am
dare
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
Low
Report
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
2/22
08:00 am
dare
Dare´ Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
High
Report
Dare´ Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
2/2
07:35 am
dare
Daré Bioscience, Inc. (NASDAQ: DARE) was downgraded by analysts at Dawson James from a "buy" rating to a "neutral" rating.
Low
Report
Daré Bioscience, Inc. (NASDAQ: DARE) was downgraded by analysts at Dawson James from a "buy" rating to a "neutral" rating.
1/31
08:00 am
dare
Dare´ Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
Medium
Report
Dare´ Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
1/26
04:30 pm
dare
Dare´ Bioscience Announces Executive Team and Board of Directors Changes
Medium
Report
Dare´ Bioscience Announces Executive Team and Board of Directors Changes